Pacer Advisors
NTLA icon

Pacer Advisors’s Intellia Therapeutics NTLA Stock Holding History

Pacer Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,186
Closed -$26.5K – 2644
2024
Q2 		$26.5K Sell
1,186
-241
-17% -$5.74K ﹤0.01% 3374
2024
Q1 		$39.3K Buy
+1,427
New +$39.6K ﹤0.01% 3266
2021
Q2 		– Sell
-1,189
Closed -$95K – 1501
2021
Q1 		$95K Sell
1,189
-1,282
-52% -$86.1K ﹤0.01% 1302
2020
Q4 		$134K Sell
2,471
-208
-8% -$7.55K ﹤0.01% 1311
2020
Q3 		$53K Buy
+2,679
New +$55.9K ﹤0.01% 1303
2018
Q4 		– Sell
-7,558
Closed -$216K – 882
2018
Q3 		$216K Buy
+7,558
New +$220K 0.01% 1021

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pacer Advisors's NTLA Position: Q3 2024 in Review

Pacer Advisors sold out of Intellia Therapeutics (NTLA) in Q3 2024, closing a stake of 1,186 shares — an estimated $26.5K sold.

Pacer Advisors first reported a position in NTLA in Q3 2018 and held it in 6 quarters. The position peaked at $216K in Q3 2018. 283 funds tracked by Wall St. Rank hold NTLA as of Q3 2024.

  • Pacer Advisors reported no remaining Intellia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 1,186 Intellia Therapeutics shares in Q3 2024, an estimated $26.5K.
  • Pacer Advisors first reported a position in Intellia Therapeutics in Q3 2018 and held it in 6 quarters.
  • Pacer Advisors's Intellia Therapeutics position peaked at $216K in Q3 2018.
  • 283 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.